Adjuvanted influenza vaccines

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Human Vaccines & Immunotherapeutics

• Publication date

  2018-01-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/21645515.2017.1415684PMID 29232151PMCID PMC5861793
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

  2018cited by this paper
• Safety and immunogenicity of the novel seasonal preservative‐ and adjuvant‐free influenza vaccine: Blind, randomized, and placebo‐controlled trial

  2018cited by this paper
• Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea

  2017cited by this paper
• Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®

  2017cited by this paper
• The synergistic effects of combining TLR ligand based adjuvants on the cytokine response are dependent upon p38/JNK signalling

  2017cited by this paper
• A novel preservative‐free seasonal influenza vaccine safety and immune response study in the frame of preclinical research

  2017cited by this paper
• Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses

  2017cited by this paper
• Dose sparing and the lack of a dose–response relationship with an influenza vaccine in adult and elderly patients – a randomized, double‐blind clinical trial

  2017cited by this paper
• Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis.

  2017cited by this paper
• Vaccine Adjuvants

  2017cited by this paper
• Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine

  2017cited by this paper
• Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans

  2017cited by this paper
• Inflammatory responses to influenza vaccination at the extremes of age

  2017cited by this paper
• Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody Titre

  2017cited by this paper
• Erratum: Airway T cells protect against RSV infection in the absence of antibody

  2017cited by this paper
• An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection

  2016cited by this paper
• Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982–2012: A Systematic Analysis

  2016cited by this paper
• Mechanistic insights into influenza vaccine-associated narcolepsy

  2016cited by this paper
• Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.

  2016cited by this paper
• Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant

  2016cited by this paper
• From discovery to licensure, the Adjuvant System story

  2016cited by this paper
• Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines

  2016cited by this paper
• A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.

  2016cited by this paper
• Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens

  2016cited by this paper
• Dissecting the Immune Response to MF59-adjuvanted and Nonadjuvanted Seasonal Influenza Vaccines in Children Less Than Three Years of Age

  2015cited by this paper
• Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination

  2015cited by this paper
• Early Estimates of Seasonal Influenza Vaccine Effectiveness — United States, January 2015

  2015cited by this paper
• Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.

  2015cited by this paper
• Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.

  2015cited by this paper
• Influenza vaccination in children primed with MF59®-adjuvanted or non-adjuvanted seasonal influenza vaccine

  2015cited by this paper
• MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life

  2015cited by this paper
• Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2

  2015cited by this paper
• Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015.

  2015cited by this paper
• Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head

  2015cited by this paper
• The path forward.

  2015cited by this paper
• The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm

  2015cited by this paper
• RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection

  2015cited by this paper
• BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study.

  2015cited by this paper
• Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets

  2015cited by this paper
• H3N2 Mismatch of 2014–15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps

  2015cited by this paper
• Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine

  2015cited by this paper
• Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.

  2014cited by this paper
• High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine

  2014cited by this paper
• Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.

  2014cited by this paper
• Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.

  2014cited by this paper
• Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.

  2014cited by this paper
• Maternal Antibodies: Clinical Significance, Mechanism of Interference with Immune Responses, and Possible Vaccination Strategies

  2014cited by this paper
• Using Plasmids as DNA Vaccines for Infectious Diseases

  2014cited by this paper
• Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

  2014cited by this paper
• Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection.

  2014cited by this paper
• Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.

  2014cited by this paper
• The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect.

  2013cited by this paper
• Chemokines as Cancer Vaccine Adjuvants

  2013cited by this paper
• Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis

  2013cited by this paper
• Mechanisms of Action of Adjuvants

  2013cited by this paper
• Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.

  2013cited by this paper
• The history of MF59® adjuvant: a phoenix that arose from the ashes

  2013cited by this paper
• Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

  2013cited by this paper
• Cellular immune correlates of protection against symptomatic pandemic influenza

  2013cited by this paper
• Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial

  2013cited by this paper
• Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells

  2013cited by this paper
• Early Estimates of Seasonal Influenza Vaccine Effectiveness — United States, January 2013

  2013cited by this paper
• Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant.

  2013cited by this paper
• First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

  2013cited by this paper
• Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

  2013cited by this paper
• The mechanism of action of MF59 - an innately attractive adjuvant formulation.

  2012cited by this paper
• Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older

  2012cited by this paper
• Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008.

  2012cited by this paper
• Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

  2012cited by this paper
• Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro

  2012cited by this paper
• Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens.

  2012cited by this paper
• A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.

  2012cited by this paper
• Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age

  2012cited by this paper
• Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response.

  2012cited by this paper
• Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant.

  2012cited by this paper
• Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine

  2012cited by this paper
• Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

  2012cited by this paper
• Structural vaccinology starts to deliver

  2012cited by this paper
• Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains.

  2012cited by this paper
• T‐cell‐inducing vaccines – what’s the future

  2012cited by this paper
• AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method.

  2012cited by this paper
• Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to 1 Year After Immunization With a Pandemic A/H1N1 Influenza Vaccine in Children 3 to <9 Years of Age

  2012cited by this paper
• AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

  2012cited by this paper
• Antigen depot is not required for alum adjuvanticity

  2012cited by this paper
• Influenza virosomes as a vaccine adjuvant and carrier system

  2011cited by this paper
• Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59

  2011cited by this paper
• Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial.

  2011cited by this paper
• Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

  2011cited by this paper
• Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes.

  2011cited by this paper
• Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study

  2011cited by this paper
• A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.

  2011cited by this paper
• Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88

  2011cited by this paper
• Influenza virosomes as vaccine adjuvant and carrier system

  2011cited by this paper
• First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

  2011cited by this paper
• Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

  2011cited by this paper
• Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis.

  2011cited by this paper
• The controversial relationship between NLRP3, alum, danger signals and the next‐generation adjuvants

  2010cited by this paper
• Influenza and Meningococcal Vaccinations Are Effective in Healthy Subjects Treated with the Interleukin-1β-Blocking Antibody Canakinumab: Results of an Open-Label, Parallel Group, Randomized, Single-Center Study

  2010cited by this paper
• Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

  2010cited by this paper
• Targeting Toll-like receptors: emerging therapeutics?

  2010cited by this paper

• Carbohydrate fatty acid monosulphate ester adjuvant enhances the immunogenicity of influenza antigens via TLR4/2-dependent mechanisms

  2026cites this paper
• Influenza vaccination coverage and associated factors among medical students in Egypt: A cross-sectional multicenter study

  2025cites this paper
• Development of universal influenza vaccines: strategies for broadly cross-reactive influenza vaccine responses

  2025cites this paper
• Dietary supplementation of arachidonic acid promotes humoral immunity

  2025cites this paper
• Guided design for the development of an evolution-proof influenza vaccine.

  2025cites this paper
• Glucose Metabolism and Innate Immune Responses in Influenza Virus Infection: Mechanistic Insights and Clinical Perspectives

  2025cites this paper
• Naringenin as a phytogenic adjuvant systematically enhances the protective efficacy of H9N2 inactivated vaccine through coordinated innate-adaptive immune priming in chickens

  2025cites this paper
• Comparison of Adjuvant Potency of Alum, AddaVax, and ISA 71 VG on the Seasonal Split Influenza Vaccine in Mice

  2025cites this paper
• Understanding the Implications of Delaying Seasonal Influenza Vaccine Recommendations: An Industry Perspective

  2025cites this paper
• Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model

  2025cites this paper
• Aging and Immunity: Challenges, Insights and Breakthrough Solutions

  2025cites this paper
• Advax®-adjuvanted inactivated influenza vaccine provides accelerated protection of mice via early induction of an influenza-specific IgM response.

  2025cites this paper
• Advances and prospects of respiratory mucosal vaccines: mechanisms, technologies, and clinical applications

  2025cites this paper
• Nanostructured lipid-based adjuvants and delivery systems for antiviral vaccine development

  2025cites this paper
• Spatiotemporal Dynamic Immunomodulation by Infection‐Mimicking Gels Enhances Broad and Durable Protective Immunity Against Heterologous Viruses

  2025cites this paper
• Vaccine adjuvants: Insights into development, present and future perspective

  2025cites this paper
• Influenza Vaccines: Current Status, Adjuvant Strategies, and Efficacy

  2025influential citation
• Multivalent COBRA Hemagglutinin and Neuraminidase Influenza Vaccines Adjuvanted with TLR9 Agonist CpG 1018

  2025cites this paper
• Systemic reactogenicity is a correlate of MF59 adjuvant-moderated immunogenicity in influenza vaccinated children

  2025cites this paper
• Recent developments of vaccines for older adults: Adjuvants and beyond

  2025cites this paper
• State of the Art and Emerging Technologies in Vaccine Design for Respiratory Pathogens

  2025cites this paper
• Evaluation of the effect of two adjuvants coadministered with nasal recombinant hemagglutinin influenza vaccine on immune cells in mice.

  2025cites this paper
• Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants.

  2025cites this paper
• Vaccination Strategies and Research Gaps in Hepatitis E Virus for Special Populations

  2025cites this paper
• Cladophora wrightiana Var. Minor Extract Acts as an Adjuvant to Promote Natural Killer Cell Activation by Nasal Influenza Vaccine

  2025cites this paper
• Innovations and challenges in vaccine development: Lessons from the SARS-CoV-2 pandemic and prospects.

  2025cites this paper
• Development of α-Tocopherol Loaded PLGA Nanoparticles and Its Evaluation as a Novel Immune Adjuvant.

  2024cites this paper
• Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021

  2024cites this paper
• Autoimmune/Inflammatory Syndrome Induced by Adjuvants

  2024cites this paper
• Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine for older adults in South Korea

  2024cites this paper
• Mastoparan-7 adjuvanted COBRA H1 and H3 hemagglutinin influenza vaccines

  2024cites this paper
• Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022–2023 Influenza Season Among Adults ≥65 Years of Age

  2024cites this paper
• Deciphering immune responses: a comparative analysis of influenza vaccination platforms.

  2024cites this paper
• Recent advances in the influenza virus vaccine landscape: a comprehensive overview of technologies and trials

  2024cites this paper
• Microfluidic-Chip-Based Formulation and In Vivo Evaluations of Squalene Oil Emulsion Adjuvants for Subunit Vaccines

  2024cites this paper
• Adjuvant potential of Peyssonnelia caulifera extract on the efficacy of an influenza vaccine in a murine model

  2024cites this paper
• Impact of sex on humoral immunity with live influenza B virus vaccines in mice

  2024cites this paper
• Optimization of formulation and device design for carrier-based nasal powder of influenza vaccine to maximize the delivery capability to the target site in the nasal cavity

  2024cites this paper
• Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England

  2024cites this paper
• Computationally Optimized Hemagglutinin Proteins Adjuvanted with Infectimune® Generate Broadly Protective Antibody Responses in Mice and Ferrets

  2024cites this paper
• Advax-SM™-Adjuvanted COBRA (H1/H3) Hemagglutinin Influenza Vaccines

  2024cites this paper
• A Transgenic Mouse With a Humanized B-Cell Repertoire Mounts an Antibody Response to Influenza Infection and Vaccination

  2024cites this paper
• Concurrent Administration of COVID-19 and Influenza Vaccines Enhances Spike-Specific Antibody Responses

  2024cites this paper
• Antigenic Divergence from the Seasonal Vaccine of the Influenza Virus Strains Circulating in Romania During Three Successive Seasons (2021–2024)

  2024cites this paper
• Transient Myopia and Ciliochoroidal Effusion following Influenza Vaccination

  2024cites this paper
• Adjuvants for COVID-19 Vaccines

  2023cites this paper
• Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice

  2023cites this paper
• A mini review for lipid-based nanovaccines: from their design to their applications

  2023cites this paper
• Does prior vaccination affect the immune response to seasonal influenza vaccination among older adults? Findings from a prospective cohort study in a Northeastern Province of Thailand

  2023cites this paper
• Exercise With a Novel Digital Device Increased Serum Anti-influenza Antibody Titers After Influenza Vaccination

  2023cites this paper
• Determining role of thymus in immune pathogenesis of autoimmune, oncological and infectious diseases

  2023cites this paper
• 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

  2023cites this paper
• Potential cross-species transmission of highly pathogenic avian influenza H5 subtype (HPAI H5) viruses to humans calls for the development of H5-specific and universal influenza vaccines

  2023cites this paper
• 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

  2023cites this paper
• Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• Effects of influenza vaccination on the morbidity and severity of COVID-19 in children

  2023cites this paper
• Seasonality as a driver of pH1N12009 influenza vaccination campaign impact.

  2023cites this paper
• Adjuvant-Mediated Differences in Antibody Responses to Computationally Optimized Hemagglutinin and Neuraminidase Vaccines

  2023cites this paper
• Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation amongst adults aged 75 years and older in England, estimated using a test-negative case control study design.

  2023cites this paper
• Longitudinal Analysis of Neuraminidase and Hemagglutinin Antibodies to Influenza A Viruses after Immunization with Seasonal Inactivated Influenza Vaccines

  2023cites this paper
• Involvement of Dectin-2 in the Innate Inflammatory Response Triggered by Influenza Virus Hemagglutinin

  2023cites this paper
• Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) - past, present, and future implications.

  2023cites this paper
• Oral Administration of Cancer Vaccines: Challenges and Future Perspectives

  2023cites this paper
• Advances in Adjuvanted Influenza Vaccines

  2023cites this paper
• Immune Response Profile Induced by Combined Alum and Glycyrrhizin Liposomes in Balb/c Mice Immunized with Ovalbumin

  2023cites this paper
• A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine

  2023cites this paper
• Validation of Multi-epitope Peptides Encapsulated in PLGA Nanoparticles Against Influenza A Virus

  2023cites this paper
• Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD)

  2023cites this paper
• The convergent evolution of influenza A virus: Implications, therapeutic strategies and what we need to know

  2023cites this paper
• Formulation of Recombinant H1N1 Hemagglutinin in MF59 and Alum Adjuvants: A Comparison of the Vaccines Potency and Efficacy in BALB/C Mice

  2023cites this paper
• Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age

  2022influential citation
• Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age

  2022cites this paper
• Systematic review of the efficacy, effectiveness and safety of high‐dose seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age

  2022cites this paper
• Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases

  2022cites this paper
• Nucleic acid vaccines: A rising antidote for the future

  2022cites this paper
• Licensed liposomal vaccines and adjuvants in the antigen delivery system

  2022cites this paper
• Vaccine-Associated Enhanced Respiratory Disease following Influenza Virus Infection in Ferrets Recapitulates the Model in Pigs

  2022cites this paper
• A comparison of cancer vaccine adjuvants in clinical trials.

  2022cites this paper
• Nanocarriers-Assisted Needle-Free Vaccine Delivery Through Oral and Intranasal Transmucosal Routes: A Novel Therapeutic Conduit

  2022cites this paper
• From Sharks to Yeasts: Squalene in the Development of Vaccine Adjuvants

  2022cites this paper
• Viral and non‐viral gene therapy using 3D (bio)printing

  2022cites this paper
• Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.

  2022cites this paper
• Cultivated Artemisia rupestris L. polysaccharide CARP2 as an adjuvant for influenza vaccines to prolong immune responses.

  2022cites this paper
• Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus

  2022cites this paper
• A Dual Adjuvant System for Intranasal Boosting of Local and Systemic Immunity for Influenza Vaccination

  2022cites this paper
• The role of cell-mediated immunity against influenza and its implications for vaccine evaluation

  2022cites this paper
• How Are Older Adults Different Than Other Adults for Infections?

  2022cites this paper
• Controlled Human Infection Models To Accelerate Vaccine Development

  2022cites this paper
• Protective and vaccine dose-sparing efficacy of Poly I:C-functionalized calcium phosphate nanoparticle adjuvants in inactivated influenza vaccination.

  2022cites this paper
• Development of Nasal Vaccines and the Associated Challenges

  2022cites this paper
• Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs

  2022cites this paper
• Preclinical study of immunogenicity of adjuvanted quadrivalent subunit influenza vaccine

  2022cites this paper
• A Review on Equine Influenza from a Human Influenza Perspective

  2022cites this paper
• Structural Stability and Antigenicity of Universal Equine H3N8 Hemagglutinin Trimer upon Release from Polyanhydride Nanoparticles and Pentablock Copolymer Hydrogels.

  2022cites this paper
• Quadrivalent Vaccines for the Immunization of Adults against Influenza: A Systematic Review of Randomized Controlled Trials

  2022cites this paper
• Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-β-cyclodextrin: A phase 1 clinical trial.

  2022cites this paper
• Multi-component prime-boost Chlamydia trachomatis vaccination regimes induce antibody and T cell responses and accelerate clearance of infection in a non-human primate model

  2022cites this paper
• Immunomodulatory Effects of α-Tocopherol on the H1N1 Influenza Vaccine: Improving the Potency and Efficacy of the Influenza Vaccine in Aged Mice

  2022cites this paper
• Chrysin enhances antitumour immunity response through the IL‐12‐STAT4 signal pathway in the B16F10 melanoma mouse model

  2022cites this paper
• Self-Assembling Nanovaccine Confers Complete Protection Against Zika Virus Without Causing Antibody-Dependent Enhancement

  2022cites this paper